NCT02176551

Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Product 0405 To A Vehicle Control In The Treatment Of Mild To Moderate Atopic Dermatitis In Pediatric Subjects

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Fougera Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 3 Months – 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of product 0405 in pediatric subjects with Mild to Moderate Atopic Dermatitis.

Detailed description

Treatment medication will be administered topically twice daily for 28 days

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Product 0405	Product 0405 will be administered topically twice daily for 28 days.
DRUG	Placebo for Product 0405	Placebo for Product 0405 will be administered topically twice daily for 28 days.

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-05-01
• Completion: 2013-05-01
• First posted: 2014-06-27
• Last updated: 2014-06-27